AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Bioequivalence Study
Phase 1
Completed
- Conditions
- Diabetes
- Interventions
- Drug: Saxagliptin/Metformin
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT01874080
- Locations
- 🇺🇸
Icon Development Solutions, San Antonio, Texas, United States
A Study of AZD4901 in Females With Polycystic Ovary Syndrome
Phase 2
Completed
- Conditions
- Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
- Interventions
- Drug: AZD4901 (oral)Drug: Placebo to match AZD4901
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 67
- Registration Number
- NCT01872078
- Locations
- 🇬🇧
Research Site, London, United Kingdom
🇺🇸Miami Research Associates, Miami, Florida, United States
Brilinta DaYu Study
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2004
- Registration Number
- NCT01870921
- Locations
- 🇨🇳
Research Site, Zhongshan, China
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
Terminated
- Conditions
- Stable Coronary Artery Disease (CAD), Myocardial Infarction
- First Posted Date
- 2013-06-03
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9284
- Registration Number
- NCT01866904
- Locations
- 🇻🇪
Research Site, Caracas, Miranda, Venezuela
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
Phase 4
Completed
- Conditions
- Non-ST or ST Elevation Acute Coronary Syndromes
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01864005
- Locations
- 🇨🇳
Research Site, Tianjin, China
Topical Roflumilast in Adults With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vehicle CreamDrug: 0.5% Roflumilast Cream
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT01856764
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01851265
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Phase 3
Active, not recruiting
- Conditions
- Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IVBRCA MutationComplete ResponsePartial ResponseFirst Line Platinum Chemotherapy
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT01844986
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Univ Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase 3
Terminated
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT01843062
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma MetastaticAdvanced Adult Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT01839604
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan